GH1 and influenza: The immunogenicity has been confirmed in a phase I clinical trial (NCT00819013).57–60 In addition, globular head domain (gH1)-Qbeta, a fully bacterially produced influenza vaccine, was obtained by chemically conjugating the gH1 of hemagglutinin (HA) from the pandemic A/California/07/2009(H1N1) influenza strain to the Qbeta VLPs.